As a pioneer of quality antibiotics since its foundation in 1974, PT. Meiji Indonesia as a subsidiary of Meiji Seika Pharma Co.,Ltd. Japan, is currently one of the few players in this sector delivering highest production quality standards in Indonesia.
History
2020
This year has been a difficult year for many companies due to the Covid-19 pandemic that has hit the world. However, this year PT. Meiji Indonesia can still spread its wings by launching several new products from the Ethical sector and also OTC sector, namely Babydex-A® MS Cream.
2019
To support our strategic moves and initiatives, we have accomplished our strategic expansion of our facilities, including our new Head Office to ensure long-term journey to serve the country and the world. Further expansion of our product portfolio continues to take place with the introduction of the new products in OTC sector - Ediva Series®, and Ophthalmology products in the Ethical sector.
2018
In line with the increasing production capacity, a new warehouse occupying 1,377 sqm of space, dedicated for ß-Lactam product packaging materials was officially in use.
2017
A new product under Skin Care category - Sakura Collagen®, was launched, followed by a Household Medical Supplies Product - Rubysta®.
2016
A baby product - Babydex-A®, was launched in line with the Company's conception of new values.
2014
On May 13th, 2014, PT. Meiji Indonesia celebrated its 40th anniversary in Surabaya.
2013
The lyophilized project was established to produce lyophilized sterile injection. This new facility has even widely spanned our penetration of specific medicine demanded by global market.
2011
In order to guarantee the quality of our new materials, in this year we established our API production facility. The API is formulated through a series of examinations, improvements, and verifications. Then, the raw materials are processed into finished products which are exported to overseas market.
2009
We received a series of awards from Meiji Headquarters in Japan as the highest business performance among Meiji Group globally in 2009, 2010, 2013, 2015,2016, and 2018.
2001
The establishment of ß-Lactam 3 plant was completed to meet export demand.
1997
Establishment of ß-Lactam 2 plant was completed.
1994
The Food and Drug Administration (BPOM) issues Good Manufacturing Practices (GMP) certificates for all product categories. The awarding of this certificate encourages the achievement of certification for our production quality in the following years.
1983
Meiji Seika Kaisha (currently Meiji Seika Pharma Co., Ltd.) Japan granted a trust to produce Kanamycin API (Active Pharmaceutical Ingredient) since 1983-1991, followed by Ampicillin API since 1991-1998.
1982
In compliance with GMP (Good Manufacturing Practices) regulation, ß-Lactam and Non ß-Lactam production must be placed under separate building, therefore the ß-Lactam 1 plant was established as a continuation of this regulation.
1974
A ß-Lactam facility at Bangil was the early origin of our present enterprise.
Scroll horizontally to view more →